Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER study of Icosapent Ethyl in coronary artery disease with hypertriglyceridemia
CTR20254592Phase 4Active
- Sponsor
- 不适用/ 亿腾医药（苏州）有限公司
- Start
- Nov 2025
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of omega-3-acid triglycerides in coronary arteriosclerosis, hypertriglyceridemia, sponsored by 不适用/ 亿腾医药（苏州）有限公司. Started Nov 2025; status: active.
02
Drugs
omega-3-acid triglycerides
03
Conditions
coronary arteriosclerosishypertriglyceridemia
Beyond the preview
Go deeper on CTR20254592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254592.